MedTrace Logo

NRX-101 Expanded Access

NCT05779267 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-07-20

No results posted yet for this study

Summary

The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical trial. The objective of the program is to provide treatment access while monitoring safety in the context of NRX-101 administration paired with theta burst transcranial magnetic stimulation..

Conditions

  • Treatment-Resistant Depression

Interventions

DRUG

NRX-101

D-cycloserine/lurasidone fixed dose combination

DEVICE

Transcranial Magnetic Stimulation Sham

transcranial magnetic stimulation will be employed and has shown effect in this population

Sponsors & Collaborators

  • NeuroRx, Inc.

    lead INDUSTRY

Principal Investigators

  • Jonathan C Javitt, MD, MPH · NRx Pharma, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05779267 on ClinicalTrials.gov